Cargando…
Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study
BACKGROUND/AIM: To evaluate the applicability of transarterial chemoembolization (TACE) treatment with doxorubicin drug-eluting beads (DEBs) in advanced hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI). METHODS: This prospective study was approved by the institutional review b...
Autores principales: | Yu, Su Jong, Lee, Yun Bin, Cho, Eun Ju, Lee, Jeong-Hoon, Kim, Hyo-Cheol, Chung, Jin Wook, Yoon, Jung-Hwan, Kim, Yoon Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Liver Cancer Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202235/ https://www.ncbi.nlm.nih.gov/pubmed/37384028 http://dx.doi.org/10.17998/jlc.2023.02.08 |
Ejemplares similares
-
Effectiveness of drug-eluting bead transarterial chemoembolization
versus conventional transarterial chemoembolization for small hepatocellular
carcinoma in Child-Pugh class A patients
por: Lee, In Joon, et al.
Publicado: (2019) -
Clinical outcomes of doxorubicin-eluting CalliSpheres beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma
por: Bi, Yonghua, et al.
Publicado: (2021) -
Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads
por: Bi, Yonghua, et al.
Publicado: (2022) -
Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022) -
Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma
por: Nam, Hee Chul, et al.
Publicado: (2016)